The Evaluation of Effectiveness and Safety for New Therapy With Bone Marrow Derived Autologous Mesenchymal Stem Cell for Hepatic Failure Caused by Alcoholic Liver Cirrhosis
The trial, sponsored by Yonsei University, investigates the use of autologous BM-MSCs for treating alcoholic liver cirrhosis, a significant unmet medical need given the rising prevalence of liver diseases globally. If successful, this therapy could position itself in a niche market with limited competition, particularly in the context of regenerative medicine for liver conditions. The commercial potential is underscored by the increasing focus on cell-based therapies and the growing demand for innovative treatments in hepatology. Diligence should focus on regulatory pathways, potential reimbursement scenarios, and the scalability of BM-MSC production.
Indication: Alcoholic Liver Cirrhosis
Modality: protein therapy
Target: Bone marrow derived autologous mesenchymal stem cells (BM-MSCs) targeting hepatic fibrosis and liver regeneration.
Sponsor: Yonsei University
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 15, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Bone marrow derived autologous mesenchymal stem cells (BM-MSCs) targeting hepatic fibrosis and liver regeneration.
View original source fields
Condition raw: Alcoholic Liver Cirrhosis
Condition normalized: Alcoholic Liver Cirrhosis
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: Bone marrow derived autologous mesenchymal stem cells (BM-MSCs) targeting hepatic fibrosis and liver regeneration.
Target normalized: Bone marrow derived autologous mesenchymal stem cells (BM-MSCs) targeting hepatic fibrosis and liver regeneration.